Alyson Polanco, in Fredericksburg, VA - Contractor

Alyson Polanco, is a Contractor based in Fredericksburg, Virginia. Alyson Polanco is licensed to practice in Ohio (license number 006809) and her current practice location is 60 Brimley Dr, Fredericksburg, Virginia. She can be reached at her office (for appointments etc.) via phone at (540) 552-6262.

NPI number for Alyson Polanco is 1043407836 and her current mailing address is 2200 Gause Blvd E, Slidell, Louisiana. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1043407836.

Contact Information

	Alyson Polanco,
	60 Brimley Dr, Fredericksburg, VA 22406-5148
	(540) 552-6262
	Not Available

Healthcare Provider's Profile

Full Name	Alyson Polanco
Gender	Female
Speciality	Contractor
Location	60 Brimley Dr, Fredericksburg, Virginia
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1043407836
Provider Enumeration Date: 09/26/2007
Last Update Date: 01/28/2021

Medical Identifiers

Medical identifiers for Alyson Polanco such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1043407836	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225X00000X	Occupational Therapist	0119006721 (Virginia)	Secondary
171W00000X	Contractor	006809 (Ohio)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Alyson Polanco is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Alyson Polanco, 2200 Gause Blvd E, Slidell, LA 70461-4223 Ph: (985) 781-4545	Alyson Polanco, 60 Brimley Dr, Fredericksburg, VA 22406-5148 Ph: (540) 552-6262

News Archive

Synageva announces 12-week data from sebelipase alfa Phase I/II study on LAL Deficiency

Synageva BioPharma Corp. (Synageva), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced publication of the 12-week Phase I/II extension study data of sebelipase alfa in adults with lysosomal acid lipase deficiency (LAL Deficiency) in the online version and an upcoming print edition of Hepatology

New book provides the latest updates on obesity research

Obesity, defined as excessive fat accumulation that may impair health, has seen its prevalence increase to unprecedented levels globally, being projected to continue to rise.

Advances in tissue engineering

Some patients wish they had a second skin - for instance because their own skin has been burnt in a severe accident.

Antibiotic resistance potentially threatens the safety and efficacy of surgical procedures and immunosuppression therapies

This week The Lancet Infectious Diseases journal published the strongest evidence to date that increasing antibiotic resistance could have disastrous consequences for patients undergoing surgery or cancer chemotherapy. Based on a review of published literature, researchers predict that a 30% reduction in the efficacy of the prophylactic antibiotics routinely given when these procedures are performed could result in 120,000 more infections and 6300 infection-related deaths every year in the USA alone.

Alyson Polanco, - in Fredericksburg, VA